CANbridge Pharma Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Public

  • Employees
  • 67

Employees

  • Stock Symbol
  • 01228

Stock Symbol

  • Share Price
  • $0.09
  • (As of Wednesday Closing)

CANbridge Pharma General Information

Description

Canbridge Pharmaceuticals Inc is a biotechnology company committed to the research, development, and commercialization of biotech therapies targeting rare diseases and rare oncology. Its differentiated drug portfolio comprises both approved drugs and a pipeline of assets, targeting prevalent rare disease indications that have unmet needs and market potential. The group's approved products include Hunterase (CAN101) for the treatment of MPS II and Livmarli for the treatment of ALGS. The various other drug candidates in its development pipeline include CAN 103, CAN 107, CAN 104, CAN 105, and CAN 204, spanning biologics, small molecules, and gene therapy, targeting prevalent rare diseases and oncology indications. Geographically, it derives revenue from Chinese Mainland and other regions.

Contact Information

Ownership Status
Publicly Held
Financing Status
Venture Capital-Backed
Corporate Office
  • Unit 18, 6th Floor, Building 21
  • No.388 Xinping Street Suzhou Industrial Park
  • Suzhou
  • China
+86 010
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
HKG
Vertical(s)
Corporate Office
  • Unit 18, 6th Floor, Building 21
  • No.388 Xinping Street Suzhou Industrial Park
  • Suzhou
  • China
+86 010

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CANbridge Pharma Stock Performance

As of 09-Jul-2025, CANbridge Pharma’s stock price is $0.09. Its current market cap is $37.3M with 425M shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.09 $0.07 $0.01 - $0.11 $37.3M 425M 7.05M -$0.14

CANbridge Pharma Financials Summary

As of 31-Dec-2024, CANbridge Pharma has a trailing 12-month revenue of $11.9M.

In Thousands,
USD
TTM 31-Dec-2024 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 22,876 22,876 37,347 66,472
Revenue 11,860 11,860 14,540 11,726
EBITDA (56,762) (56,762) (49,811) (68,086)
Net Income (61,685) (61,685) (53,547) (71,790)
Total Assets 16,002 16,002 55,774 101,756
Total Debt 18,599 18,599 20,022 22,507
Public Fundamental Data provided by Morningstar, Inc. disclaimer

CANbridge Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore CANbridge Pharma‘s full profile, request access.

Request a free trial

CANbridge Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Canbridge Pharmaceuticals Inc is a biotechnology company committed to the research, development, and commercialization o
Pharmaceuticals
Suzhou, China
67 As of 2024

La Jolla, CA
 

Shanghai, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CANbridge Pharma Competitors (61)

One of CANbridge Pharma’s 61 competitors is Inhibrx, a Formerly VC-backed company based in La Jolla, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Inhibrx Formerly VC-backed La Jolla, CA
Innovent Biologics Formerly PE-Backed Shanghai, China
BeOne Medicines Formerly PE-Backed Beijing, China
Dicerna Pharmaceuticals Formerly VC-backed Lexington, MA
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA
You’re viewing 5 of 61 competitors. Get the full list »

CANbridge Pharma Patents

CANbridge Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3644062-B1 Method for predicting esophagus cancer response to anti-erbb3 antibody treatment Active 22-Jun-2017
EP-3644062-C0 Method for predicting esophagus cancer response to anti-erbb3 antibody treatment Active 22-Jun-2017
EP-3644062-A1 Method for predicting response of esophagus cancer to anti-erbb3 antibody therapy, and kit Active 22-Jun-2017
EP-3644062-A4 Method for predicting response of esophagus cancer to anti-erbb3 antibody therapy, and kit Active 22-Jun-2017
US-11834716-B2 Method for predicting response of esophagus cancer to anti-erbb3 antibody therapy, and kit Active 22-Jun-2017 C12Q1/6886
To view CANbridge Pharma’s complete patent history, request access »

CANbridge Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CANbridge Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore CANbridge Pharma‘s full profile, request access.

Request a free trial

CANbridge Pharma FAQs

  • When was CANbridge Pharma founded?

    CANbridge Pharma was founded in 2012.

  • Where is CANbridge Pharma headquartered?

    CANbridge Pharma is headquartered in Suzhou, China.

  • What is the size of CANbridge Pharma?

    CANbridge Pharma has 67 total employees.

  • What industry is CANbridge Pharma in?

    CANbridge Pharma’s primary industry is Pharmaceuticals.

  • Is CANbridge Pharma a private or public company?

    CANbridge Pharma is a Public company.

  • What is CANbridge Pharma’s stock symbol?

    The ticker symbol for CANbridge Pharma is 01228.

  • What is the current stock price of CANbridge Pharma?

    As of 09-Jul-2025 the stock price of CANbridge Pharma is $0.09.

  • What is the current market cap of CANbridge Pharma?

    The current market capitalization of CANbridge Pharma is $37.3M.

  • What is CANbridge Pharma’s current revenue?

    The trailing twelve month revenue for CANbridge Pharma is $11.9M.

  • Who are CANbridge Pharma’s competitors?

    Inhibrx, Innovent Biologics, BeOne Medicines, Dicerna Pharmaceuticals, and Alnylam Pharmaceuticals are some of the 61 competitors of CANbridge Pharma.

  • What is CANbridge Pharma’s annual earnings per share (EPS)?

    CANbridge Pharma’s EPS for 12 months was -$0.14.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »